Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical-stage biotechnology company focused on developing immunomodulatory therapies targeting the CD40 Ligand pathway. The company's website is www.eledon.com.

Eledon's lead compound, tegoprubart, is an IgG1 anti-CD40L monoclonal antibody designed to prevent organ rejection and treat amyotrophic lateral sclerosis. The company's primary development focus centers on kidney transplantation, where tegoprubart aims to replace calcineurin inhibitors in standard immunosuppressive regimens. By blocking CD40L rather than the CD40 receptor, tegoprubart inhibits both CD40 and CD11 costimulatory signaling pathways while promoting polarization toward regulatory T cells, potentially offering improved efficacy and safety compared to existing approaches.

The company's clinical pipeline includes multiple programs. In kidney transplantation, Eledon is conducting the Phase 2 BESTOW trial, a head-to-head superiority study comparing tegoprubart to tacrolimus in approximately 120 kidney transplant recipients. The company also maintains an ongoing Phase 1b study and a Phase 2 open-label extension study evaluating long-term safety and efficacy. Additionally, tegoprubart is being evaluated in xenotransplantation through a collaborative agreement with eGenesis, with the compound used in four xenotransplantation procedures to date involving genetically modified pig organs.

Beyond transplantation, Eledon is advancing tegoprubart for islet cell transplantation in type 1 diabetes patients through an investigator-initiated trial at the University of Chicago Medicine, where preliminary data demonstrates insulin independence in treated subjects. The company previously pursued development for amyotrophic lateral sclerosis, completing a Phase 2a study showing safety and target engagement, though further ALS development requires additional financing.

Eledon's intellectual property portfolio includes ten active patent families covering isolated antibodies and treatment methods targeting CD40L-related diseases. The company relies on third-party manufacturers for drug substance and product manufacturing, with no plans to develop internal manufacturing operations. Eledon was formerly known as Novus Therapeutics, Inc., and acquired Anelixis Therapeutics in September 2020 to obtain tegoprubart and related intellectual property.